Mutations in NOTCH1 PEST Domain Orchestrate CCL19-driven Homing of Chronic Lymphocytic Leukemia Cells by Modulating the Tumor Suppressor Gene DUSP22

Overview

Journal Leukemia

Specialties Hematology
Oncology

Date 2016 Dec 27

PMID 28017968

Citations 38

Authors

F Arruga

B Gizdic

C Bologna

S Cignetto

R Buonincontri

S Serra

T Vaisitti

K Gizzi

N Vitale

G Garaffo

E Mereu

F Diop

F Neri

D Incarnato

M Coscia

J Allan

R Piva

S Oliviero

R R Furman

D Rossi

G Gaidano

S Deaglio

Affiliations

Soon will be listed here.

Abstract

Even if NOTCH1 is commonly mutated in chronic lymphocytic leukemia (CLL), its functional impact in the disease remains unclear. Using CRISPR/Cas9-generated Mec-1 cell line models, we show that NOTCH1 regulates growth and homing of CLL cells by dictating expression levels of the tumor suppressor gene DUSP22. Specifically, NOTCH1 affects the methylation of DUSP22 promoter by modulating a nuclear complex, which tunes the activity of DNA methyltransferase 3A (DNMT3A). These effects are enhanced by PEST-domain mutations, which stabilize the molecule and prolong signaling. CLL patients with a NOTCH1-mutated clone showed low levels of DUSP22 and active chemotaxis to CCL19. Lastly, in xenograft models, NOTCH1-mutated cells displayed a unique homing behavior, localizing preferentially to the spleen and brain. These findings connect NOTCH1, DUSP22, and CCL19-driven chemotaxis within a single functional network, suggesting that modulation of the homing process may provide a relevant contribution to the unfavorable prognosis associated with NOTCH1 mutations in CLL.

Citing Articles

Molecular Mechanisms in the Transformation from Indolent to Aggressive B Cell Malignancies.

Maher N, Mouhssine S, Matti B, Alwan A, Gaidano G Cancers (Basel). 2025; 17(5).

PMID: 40075754 PMC: 11899122. DOI: 10.3390/cancers17050907.

CRISPR-Cas9 in basic and translational aspects of cancer therapy.

Samareh Salavatipour M, Poursalehi Z, Hosseini Rouzbahani N, Mohammadyar S, Vasei M Bioimpacts. 2024; 14(6):30087.

PMID: 39493894 PMC: 11530967. DOI: 10.34172/bi.2024.30087.

The Role of Methylation in Chronic Lymphocytic Leukemia and Its Prognostic and Therapeutic Impacts in the Disease: A Systematic Review.

Chatzidavid S, Kontandreopoulou C, Giannakopoulou N, Diamantopoulos P, Stafylidis C, Kyrtsonis M Adv Hematol. 2024; 2024:1370364.

PMID: 38435839 PMC: 10907108. DOI: 10.1155/2024/1370364.

The molecular map of CLL and Richter's syndrome.

Sud A, Parry E, Wu C Semin Hematol. 2024; 61(2):73-82.

PMID: 38368146 PMC: 11653080. DOI: 10.1053/j.seminhematol.2024.01.009.

-mutated chronic lymphocytic leukemia displays high endoplasmic reticulum stress response with druggable potential.

Barcelos E, Rompietti C, Adamo F, Dorillo E, De Falco F, Del Papa B Front Oncol. 2023; 13:1218989.

PMID: 37817771 PMC: 10561002. DOI: 10.3389/fonc.2023.1218989.

References

Buonamici S, Trimarchi T, Ruocco M, Reavie L, Cathelin S, Mar B . CCR7 signalling as an essential regulator of CNS infiltration in T-cell leukaemia. Nature. 2009; 459(7249):1000-4. PMC: 3750496. DOI: 10.1038/nature08020. View

Vaisitti T, Audrito V, Serra S, Buonincontri R, Sociali G, Mannino E . The enzymatic activities of CD38 enhance CLL growth and trafficking: implications for therapeutic targeting. Leukemia. 2014; 29(2):356-68. DOI: 10.1038/leu.2014.207. View

Puente X, Pinyol M, Quesada V, Conde L, Ordonez G, Villamor N . Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature. 2011; 475(7354):101-5. PMC: 3322590. DOI: 10.1038/nature10113. View

Pozzo F, Bittolo T, Arruga F, Bulian P, Macor P, Tissino E . NOTCH1 mutations associate with low CD20 level in chronic lymphocytic leukemia: evidence for a NOTCH1 mutation-driven epigenetic dysregulation. Leukemia. 2015; 30(1):182-9. DOI: 10.1038/leu.2015.182. View

Malet-Engra G, Viaud J, Ysebaert L, Farce M, Lafouresse F, Laurent G . CIP4 controls CCL19-driven cell steering and chemotaxis in chronic lymphocytic leukemia. Cancer Res. 2013; 73(11):3412-24. DOI: 10.1158/0008-5472.CAN-12-3564. View

Ntziachristos P, Lim J, Sage J, Aifantis I . From fly wings to targeted cancer therapies: a centennial for notch signaling. Cancer Cell. 2014; 25(3):318-34. PMC: 4040351. DOI: 10.1016/j.ccr.2014.02.018. View

Oka M, Meacham A, Hamazaki T, Rodic N, Chang L, Terada N . De novo DNA methyltransferases Dnmt3a and Dnmt3b primarily mediate the cytotoxic effect of 5-aza-2'-deoxycytidine. Oncogene. 2005; 24(19):3091-9. DOI: 10.1038/sj.onc.1208540. View

Liu D, Zhou P, Zhang L, Gong W, Huang G, Zheng Y . HDAC1/DNMT3A-containing complex is associated with suppression of Oct4 in cervical cancer cells. Biochemistry (Mosc). 2012; 77(8):934-40. DOI: 10.1134/S0006297912080159. View

Sekine Y, Tsuji S, Ikeda O, Sato N, Aoki N, Aoyama K . Regulation of STAT3-mediated signaling by LMW-DSP2. Oncogene. 2006; 25(42):5801-6. DOI: 10.1038/sj.onc.1209578. View

10.

Landau D, Tausch E, Taylor-Weiner A, Stewart C, Reiter J, Bahlo J . Mutations driving CLL and their evolution in progression and relapse. Nature. 2015; 526(7574):525-30. PMC: 4815041. DOI: 10.1038/nature15395. View

11.

Cuesta-Mateos C, Lopez-Giral S, Alfonso-Perez M, de Soria V, Loscertales J, Guasch-Vidal S . Analysis of migratory and prosurvival pathways induced by the homeostatic chemokines CCL19 and CCL21 in B-cell chronic lymphocytic leukemia. Exp Hematol. 2010; 38(9):756-64, 764.e1-4. DOI: 10.1016/j.exphem.2010.05.003. View

12.

Rossi D, Gaidano G . Richter syndrome: pathogenesis and management. Semin Oncol. 2016; 43(2):311-9. DOI: 10.1053/j.seminoncol.2016.02.012. View

13.

Villamor N, Conde L, Martinez-Trillos A, Cazorla M, Navarro A, Bea S . NOTCH1 mutations identify a genetic subgroup of chronic lymphocytic leukemia patients with high risk of transformation and poor outcome. Leukemia. 2013; 27(5):1100-6. DOI: 10.1038/leu.2012.357. View

14.

Rossi D, Rasi S, Spina V, Bruscaggin A, Monti S, Ciardullo C . Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia. Blood. 2012; 121(8):1403-12. PMC: 3578955. DOI: 10.1182/blood-2012-09-458265. View

15.

Li J, Fu Y, Chen Y, Tan T . JNK pathway-associated phosphatase dephosphorylates focal adhesion kinase and suppresses cell migration. J Biol Chem. 2009; 285(8):5472-8. PMC: 2820775. DOI: 10.1074/jbc.M109.060186. View

16.

Nadeu F, Delgado J, Royo C, Baumann T, Stankovic T, Pinyol M . Clinical impact of clonal and subclonal TP53, SF3B1, BIRC3, NOTCH1, and ATM mutations in chronic lymphocytic leukemia. Blood. 2016; 127(17):2122-30. PMC: 4912011. DOI: 10.1182/blood-2015-07-659144. View

17.

Secchiero P, Melloni E, di Iasio M, Tiribelli M, Rimondi E, Corallini F . Nutlin-3 up-regulates the expression of Notch1 in both myeloid and lymphoid leukemic cells, as part of a negative feedback antiapoptotic mechanism. Blood. 2009; 113(18):4300-8. DOI: 10.1182/blood-2008-11-187708. View

18.

Sekine Y, Ikeda O, Hayakawa Y, Tsuji S, Imoto S, Aoki N . DUSP22/LMW-DSP2 regulates estrogen receptor-alpha-mediated signaling through dephosphorylation of Ser-118. Oncogene. 2007; 26(41):6038-49. DOI: 10.1038/sj.onc.1210426. View

19.

Yang L, Rau R, Goodell M . DNMT3A in haematological malignancies. Nat Rev Cancer. 2015; 15(3):152-65. PMC: 5814392. DOI: 10.1038/nrc3895. View

20.

Arruga F, Gizdic B, Serra S, Vaisitti T, Ciardullo C, Coscia M . Functional impact of NOTCH1 mutations in chronic lymphocytic leukemia. Leukemia. 2013; 28(5):1060-70. DOI: 10.1038/leu.2013.319. View